Want to see DMAC full AI Analyst Report?
Top Page
Diamedica Therapeutics
(NASDAQ:DMAC)
Select Model
Select Model
Rating:50Neutral
Price Target:
$8.50
▲(26.87% Upside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by weak financial performance (pre-revenue, sustained losses, and rising cash burn), partially offset by a strong low-debt balance sheet and a positive near-term clinical/regulatory milestone path from the latest earnings call. Technicals are broadly neutral, and valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Conservatively levered balance sheet
Very low leverage gives Diamedica greater financial flexibility while it funds clinical development. Meaningful equity and assets provide a buffer against near-term obligations, although preserving that flexibility will depend on controlling losses and future cash consumption.
Negative Factors
No commercial revenue and persistent losses
Diamedica has not yet demonstrated commercial revenue generation, while operating and net losses remain substantial. Until a product is approved and launched, the company lacks operating earnings to fund development, making clinical execution dependent on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservatively levered balance sheet
Very low leverage gives Diamedica greater financial flexibility while it funds clinical development. Meaningful equity and assets provide a buffer against near-term obligations, although preserving that flexibility will depend on controlling losses and future cash consumption.
Read all positive factors
Diamedica Therapeutics (DMAC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$467.54M
Dividend YieldN/A
Average Volume (3M)225.18K
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue GrowthN/A
EPS Growth-3.42%
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding53,925,697
10 Day Avg. Volume221,571
30 Day Avg. Volume225,179
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.97
Forecast
1Y Price Target
$12.00Price Target Upside79.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Diamedica Therapeutics Business Overview & Revenue Model
Company Description
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein...
How the Company Makes Money
Diamedica Therapeutics does not have an established, recurring commercial revenue base from product sales, as its lead program (DM199) is in clinical development and has not been approved for marketing; therefore, revenue from marketed products is...
Diamedica Therapeutics Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful clinical progress: completion of the first FGR cohort, a supportive Part 1a preeclampsia data set with statistically significant blood pressure reductions and improved uterine perfusion signals, regulatory advances in Canada and planned expansions, and continued progress toward the ReMEDy2 interim analysis with broad site coverage. Financially, the company maintains a cash runway through 2027 but is experiencing a notable decline in cash and working capital versus year-end and materially higher R&D spend and operating cash burn. Operational and regulatory headwinds include enrollment variability, additional rat studies required for a U.S. IND, and a nonlinear dose-response that constrains higher-dose strategies. Overall, the positive clinical momentum and defined regulatory paths outweigh the financing and operational challenges in the near term.Positive Updates
Completed Enrollment in First Cohort of Phase II Fetal Growth Restriction (FGR) Study
Enrollment completed for cohort 1 (6 participants) at 5 µg/kg in open-label Phase II IST for early onset FGR, enabling expansion of DM199 into a second serious women's health indication with no approved therapies; cohort 2 (10 µg/kg) to begin shortly and cohort 3 dose to be chosen between 1–15 µg/kg based on emerging data.
Negative Updates
Decrease in Cash and Working Capital Since Year-End
Cash and short-term investments declined from $59.9M on Dec 31, 2025 to $43.5M on June 30, 2026, a decrease of approximately 27.4%; working capital fell from $55.5M to $37.7M, a decline of approximately 32.1%.
Read all updates
Q2-2026 Updates
Positive
Negative
Completed Enrollment in First Cohort of Phase II Fetal Growth Restriction (FGR) Study
Enrollment completed for cohort 1 (6 participants) at 5 µg/kg in open-label Phase II IST for early onset FGR, enabling expansion of DM199 into a second serious women's health indication with no approved therapies; cohort 2 (10 µg/kg) to begin shortly and cohort 3 dose to be chosen between 1–15 µg/kg based on emerging data.
Read all positive updates
Company Guidance
Management guided that the company is funded through 2027 with cash, cash equivalents and short‑term investments of $43.5M as of June 30, 2026 (vs. $59.9M at 12/31/25), current liabilities $6.6M and working capital $37.7M, with net cash used in operations of $17.2M for the six months ended June 30, 2026; R&D spending was $8.2M (Q2) and $16.1M (YTD) and G&A was $2.3M (Q2) and $4.8M (YTD). Key clinical milestones and timing include ReMEDy2 having surpassed ~85% of the ~200 patients required to trigger the prespecified interim efficacy analysis (expected Q1 2027 after protocol‑defined 90‑day follow‑up and ~4–6 weeks for analysis), ~70 active sites across the U.S., Canada, U.K. and six European countries, and an interim DSMB review that could reestimate final size (range 300–728 patients or futility). For pregnancy programs, the first open‑label FGR cohort is complete (6 patients at 5 µg/kg) with cohort 2 at 10 µg/kg starting soon and cohort 3 to be chosen between 1–15 µg/kg; the Part 1a preeclampsia extension pooled 15 high‑dose patients showing mean systolic BP ↓29.1 mmHg (from 169.3, p<0.001) and diastolic BP ↓17.0 mmHg (from 103.7, p<0.01) with systolic <160 mmHg over 24 hours. Health Canada has authorized a ~30‑patient, 3‑dose open‑label Phase II early onset preeclampsia study (dosing to start in Q4 in Canada and expansion to the U.K. later this year), dosing plans begin at 5 µg/kg then 10 µg/kg (third dose 1–15 µg/kg), and a rat PK/pharmacology study completing in September (reports in October) is planned to support a U.S. IND.Diamedica Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -37.46M | -32.70M | -24.38M | -19.31M | -13.62M | -13.54M |
| Net Income | -37.54M | -32.77M | -24.44M | -19.38M | -13.68M | -13.59M |
Balance Sheet | ||||||
| Total Assets | 45.00M | 61.37M | 46.34M | 54.16M | 34.40M | 45.55M |
| Cash, Cash Equivalents and Short-Term Investments | 43.50M | 59.89M | 44.15M | 52.90M | 33.50M | 45.11M |
| Total Debt | 185.00K | 240.00K | 340.00K | 400.00K | 469.00K | 52.00K |
| Total Liabilities | 6.66M | 5.26M | 5.63M | 3.10M | 2.57M | 1.53M |
| Stockholders Equity | 38.34M | 56.11M | 40.72M | 51.06M | 31.83M | 44.02M |
Cash Flow | ||||||
| Free Cash Flow | -31.60M | -29.10M | -22.10M | -18.75M | -11.59M | -12.27M |
| Operating Cash Flow | -31.57M | -29.06M | -22.08M | -18.73M | -11.51M | -12.25M |
| Investing Cash Flow | -12.08M | -2.19M | 8.56M | -18.30M | 11.54M | -20.54M |
| Financing Cash Flow | 44.65M | 43.88M | 11.99M | 36.84M | -6.00K | 30.09M |
Diamedica Therapeutics Technical Analysis
Positive
6.70
Price Trends
7.31
Positive
6.97
Positive
7.09
Positive
Market Momentum
0.29
Negative
62.18
Neutral
81.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMAC, the sentiment is Positive. The current price of 6.7 is below the 20-day moving average (MA) of 8.17, below the 50-day MA of 7.31, and below the 200-day MA of 7.09, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 62.18 is Neutral, neither overbought nor oversold. The STOCH value of 81.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DMAC.
Diamedica Therapeutics Risk Analysis
Diamedica Therapeutics disclosed 61 risk factors in its most recent earnings report. Diamedica Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Diamedica Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $726.09M | -3.33 | -106.15% | ― | ― | 10.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $467.54M | -12.07 | -77.68% | ― | ― | -3.42% | |
46 Neutral | $315.34M | -8.67 | -28.41% | 0.12% | ― | 14.04% | |
45 Neutral | $13.61M | -0.37 | -145.40% | ― | -100.00% | 82.57% | |
45 Neutral | $384.30M | -2.40 | -56.60% | ― | -100.00% | -49.28% | |
45 Neutral | $256.87M | -13.75 | -5.76% | ― | ― | 93.45% |
* Healthcare Sector Average
DMAC
Diamedica Therapeutics
8.72
1.84
26.74%
TVRD
Tvardi Therapeutics
0.94
-4.03
-81.09%
CAPR
Capricor Therapeutics
5.93
-0.27
-4.35%
RCKT
Rocket Pharmaceuticals
2.29
-1.56
-40.52%
BNTC
Benitec Biopharma
8.65
-7.87
-47.64%
ANNX
Annexon Biosciences
3.81
0.60
18.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.